Path to progress
On India’s 75th Independence Day, a few stakeholders and their partners share their insights on the biggest achievements and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenn Saldanha
Govt of India gives ‘India Pharma Innovation of the Year’ Award to Glenmark
The Award recognises Glenmark’s patents and commercialised innovations over the last three years
Glenmark Pharma secures its position in Dow Jones Sustainability Emerging Markets Index
Glenmark Pharmaceuticals has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for…
Glenmark’s consolidated revenue rises to Rs 27,674.89 million for Q4 FY 2019-20
Consolidated net profit was at Rs 2203.08 million for the quarter ended March 31, 2019 Glenmark Pharmaceuticals, a research-led…
Glenmark Pharma approves Ryaltris in Australia
Ryaltris is a new fixed‐dose combination nasal spray of an antihistamine and a steroid indicated for treatment of symptoms…
Glenmark records a 29.89 per cent growth in Q4 FY 15-16
India Business grew at 22.52 per cent to Rs 5,397.72 million for the quarter and to Rs 21,092.72 million for the year
Union Budget 2016-17: Glenn Saldanha, Chairman and MD– Glenmark Pharmaceuticals
The budget did not announce anything specific for the pharma sector
Glenmark’s novel monoclonal antibody GBR 830 to enter phase II clinical studies
GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple…
Glenmark’s consolidated revenue increases by 11.32 per cent to Rs 16,552.48 million in Q1 FY 15-16
Consolidated net profit for Q1 FY 15-16 was Rs 1909.38 million Glenmark Pharmaceuticals announced its results for the first…
Glenmark’s consolidated revenue increases by 10.62 per cent to Rs 66447.68 million in FY 14-15
Consolidated revenue in Q4 FY14-15 was Rs 17758.13 million an increase of 4.24 per cent Glenmark Pharmaceuticals announced its…